Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies
Cost: FreeView Offer chevron_right
Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.
After reviewing Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies physiicians will be able to:
- Describe the pathophysiology of cTTP such that it might inform treatment mechanisms.
- Identify diagnostic criteria and differential diagnoses for cTTP
- Describe current treatment standards for the management of cTTP and apply them to patient cases
- Describe new and emerging therapies for the treatment of cTTP and the existing literature support its use in practice
- Evaluate the likelihood cTTP in a patient case and develop a treatment plan
Target Audience: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.